Scripps Genomic Medicine
La Jolla, California, 92037, United States
NCT Number: NCT00992420
This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
La Jolla, California, 92037, United States
AS DESCRIBED BY THE PI: This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to determine whether certain genes influence the incremental change in platelet reactivity with high-dose clopidogrel maintenance dosing in patients who have high residual platelet reactivity on standard dosing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Outcome 1 is residual platelet reactivity the measurement
Scripps Health
Other
GIFT: Genotype Information and Functional Testing Study
Acronym: GIFT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05336435
Acute Coronary Syndrome, Angina Pectoris
Aabenraa, Denmark
View Trial DetailsNCT07480629
Antiplatelet Therapy of Coronary Artery Bypass, Arterial Occlusive Diseases
Shanghai, China
View Trial DetailsNCT05406284
Arterial Occlusive Diseases, Arteriosclerosis
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial Details